払う、支払う　　　　　　　　

WordNet

render; "pay a visit"; "pay a call"
do or give something to somebody in return; "Does she pay you for the work you are doing?" (同)pay_off, make_up, compensate
be worth it; "It pays to go through the trouble"
bear (a cost or penalty), in recompense for some action; "Youll pay for this!"; "She had to pay the penalty for speaking out rashly"; "Youll pay for this opinion later"
discharge or settle; "pay a debt"; "pay an obligation"
give money, usually in exchange for goods or services; "I paid four dollars for this sandwich"; "Pay the waitress, please"
make a compensation for; "a favor that cannot be paid back"
tropical American shrub or small tree having huge deeply palmately cleft leaves and large oblong yellow fruit (同)papaia, pawpaw, papaya tree, melon tree, Carica_papaya
large oval melon-like tropical fruit with yellowish flesh
payment of a debt or obligation (同)quittance
loss resulting from failure of a debt to be paid (同)default, nonremittal
a small payment made in acknowledgement of an obligation

PrepTutorEJDIC

〈金・税金・負債など〉‘を'『支払う』;…‘に'支払う / (収益・利潤として)〈物事が〉…‘を'もたらす,支払う / 〈物事が〉…‘の'利益になる,役に立つ / 〈注意・敬意など〉‘を'『払う』;〈あいさつ・訪問など〉‘を'『する』 / (…の)支払い(償い)をする《+『for』+『名』(do『ing』)》 / 利益がある,役に立つ / 『支払い』;(特に)『賃金』,給料,俸給 / (…の)雇用,雇い(employment)《+『of』+『名』》 / 有料の,コイン式の
パパイヤ;その実(熱帯アメリカ産;実は大きく黄色)
返済,返礼 / 払い戻された物,お返し,報酬
(…の)不払い,未払い《+『of』+『名』》
退職手当
とうちゃん(papa)

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/07/31 22:41:15」(JST)

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 精神科診療における治療関係の確立と維持 establishing and maintaining a therapeutic relationship in psychiatric practice
2. 結核治療の遵守 adherence to tuberculosis treatment
3. 高血圧の有病割合およびコントロール the prevalence and control of hypertension
4. 高齢者におけるリハビリテーションの概要：リハビリテーションのプログラム構成および環境 overview of geriatric rehabilitation program components and settings for rehabilitation
5. 腎移植における非血縁生体ドナー living unrelated donors in renal transplantation

Heterogeneity in general practitioners' preferences for quality improvement programs: a choice experiment and policy simulation in France.

Ammi M1, Peyron C2.
Health economics review.Health Econ Rev.2016 Dec;6(1):44. doi: 10.1186/s13561-016-0121-7. Epub 2016 Sep 15.
Despite increasing popularity, quality improvement programs (QIP) have had modest and variable impacts on enhancing the quality of physician practice. We investigate the heterogeneity of physicians' preferences as a potential explanation of these mixed results in France, where the national voluntary
PMID 27637834

What, who and when? Incorporating a discrete choice experiment into an economic evaluation.

Tinelli M1, Ryan M2, Bond C3.
Health economics review.Health Econ Rev.2016 Dec;6(1):31. doi: 10.1186/s13561-016-0108-4. Epub 2016 Jul 29.
BACKGROUND: Economic evaluation focuses on Quality-Adjusted-Life-Years (QALYs) as the main valuation method. However, it is well known that factors beyond health related quality of life are important to patients and the public. Whilst discrete-choice-experiments (DCE) have been extensively used to v
PMID 27472943

Jedi Public Health: Co-creating an Identity-Safe Culture to Promote Health Equity.

Geronimus AT1, James SA, Destin M, Graham LA, Hatzenbuehler M, Murphy M, Pearson JA, Omari A, Thompson JP.
SSM - population health.SSM Popul Health.2016 Dec;2:105-116.
The extent to which socially-assigned and culturally mediated social identity affects health depends on contingencies of social identity that vary across and within populations in day-to-day life. These contingencies are structurally rooted and health damaging inasmuch as they activate physiological
PMID 27022616

Successful treatment for sorafenib-induced liver dysfunction: a report of case with liver biopsy.

Kuroda D1, Hayashi H1, Nitta H1, Imai K1, Abe S1, Hashimoto D1, Chikamoto A1, Ishiko T1, Beppu T1, Baba H2.
Surgical case reports.Surg Case Rep.2016 Dec;2(1):4. doi: 10.1186/s40792-016-0131-z. Epub 2016 Jan 14.
Sorafenib is an oral multikinase inhibitor with anti-proliferative and anti-angiogenic effects and is used worldwide for the treatment of advanced or metastatic hepatocellular carcinoma (HCC). While the significant survival benefit of sorafenib in patients with advanced HCC was demonstrated, various
PMID 26943680